Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients

Aging

Volumn 7, Issue 12, 2015, Pages 1130-1142

  Horvath, Steve ^a,b   Ritz, Beate R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DNA methylation; Epigenetic clock; Epigenetics; Granulocyte; Neutrophil; Parkinson's disease

Indexed keywords

LEVODOPA;

ADULT; AGED; AGING; BLOOD; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GRANULOCYTE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PARKINSON DISEASE; PHYSIOLOGY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AGING; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GRANULOCYTES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS;

EID: 84957539650     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100859     Document Type: Article

References (45)

1. Schrag A, Horsfall L, Walters K, Noyce A and Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. The Lancet Neurology. 14:57-64.
2. Schapira AH, Olanow CW, Greenamyre JT and Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet. 2014; 384:545-555.
3. Hirsch EC and Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009; 8:382-397.
4. Marttila RJ, Eskola J, Soppi E and Rinne UK. Immune functions in Parkinson's disease lymphocyte subsets, concanavalin Ainduced suppressor cell activity and in vitro immunoglobulin production. J Neurol Sci. 1985; 69:121-131.
5. Guan JZ, Maeda T, Sugano M, Oyama J, Higuchi Y, Suzuki T and Makino N. A percentage analysis of the telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci. 2008; 63:467-473.
6. Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA and Ascherio A. Telomere length and risk of Parkinson's disease. Mov Disord. 2008; 23:302-305.
7. Maeda T, Guan JZ, Oyama J, Higuchi Y and Makino N. Agingassociated alteration of subtelomeric methylation in Parkinson's disease. J Gerontol A Biol Sci Med Sci. 2009; 64:949-955.
8. Eerola J, Kananen L, Manninen K, Hellstrom O, Tienari PJ and Hovatta I. No evidence for shorter leukocyte telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci. 2010; 65:1181-1184.
9. Hudson G, Faini D, Stutt A, Eccles M, Robinson L, Burn DJ and Chinnery PF. No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol Aging. 2011; 32:2107.e2103-2105.
10. Watfa G, Dragonas C, Brosche T, Dittrich R, Sieber CC, Alecu C, Benetos A and Nzietchueng R. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J Nutr Health Aging. 2011; 15:277-281.
11. Maeda T, Guan JZ, Koyanagi M, Higuchi Y and Makino N. Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease. J Neurogenet. 2012; 26:245-251.
12. Schurks M, Buring J, Dushkes R, Gaziano JM, Zee RY and Kurth T. Telomere length and Parkinson's disease in men: a nested case-control study. Eur J Neurol. 2014; 21:93-99.
13. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B, Bibikova M, Fan J-B and Gao Y. Genome-wide methylation profiles reveal quantitative views of human aging rates. Molecular cell. 2013; 49:359-367.
14. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013; 14(R115).
15. Weidner CI, Lin Q, Koch CM, Eisele L, Beier F, Ziegler P, Bauerschlag DO, Jockel KH, Erbel R, Muhleisen TW, Zenke M, Brummendorf TH and Wagner W. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014; 15:R24.
16. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O'Donovan MC, Bray NJ and Mill J. Methylomic trajectories across human fetal brain development. Genome research. 2015; 25:338-352.
17. Marioni R, Shah S, McRae A, Chen B, Colicino E, Harris S, Gibson J, Henders A, Redmond P, Cox S, Pattie A, Corley J, Murphy L, et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. 2015; 16:25.
18. Marioni RE, Shah S, McRae AF, Ritchie SJ, Muniz-Terrera G, Harris SE, Gibson J, Redmond P, Cox SR and Pattie A. The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. International journal of epidemiology. 2015:dyu277.
19. Horvath S, Erhart W, Brosch M, Ammerpohl O, von Schönfels W, Ahrens M, Heits N, Bell JT, Tsai P-C, Spector TD, Deloukas P, Siebert R, Sipos B, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A 2014; 111:15538-15543.
20. Horvath S, Garagnani P, Bacalini M, Pirazzini C, Salvioli S, Gentilini D, DiBlasio A, Giuliani C, Tung S, Vinters H and Franceschi C. Accelerated Epigenetic Aging in Down Syndrome. Aging Cell. 2015; 14:491-495.
21. Horvath S and Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis. 2015; 212:1563-1573.
22. Levine ME, Hosgood HD, Chen B, Absher D, Assimes T and Horvath S. DNA methylation age of blood predicts future onset of lung cancer in the women's health initiative. Aging (Albany NY). 2015; 7:690-700.
23. Horvath S, Mah V, Lu AT, Woo JS, Choi OW, Jasinska AJ, Riancho JA, Tung S, Coles NS, Braun J, Vinters HV and Coles LS. The cerebellum ages slowly according to the epigenetic clock. Aging (Albany NY). 2015; 7:294-306.
24. Walker RF, Liu JS, Peters BA, Ritz BR, Wu T, Ophoff RA and Horvath S. Epigenetic age analysis of children who seem to evade aging. Aging (Albany NY). 2015; 7:334-339.
25. Lin Q and Wagner W. Epigenetic Aging Signatures Are Coherently Modified in Cancer. PLoS Genet. 2015; 11:e1005334.
26. Kananen L, Nevalainen T, Jylhävä J, Marttila S, Hervonen A, Jylhä M and Hurme M. Cytomegalovirus infection accelerates epigenetic aging. Experimental Gerontology. 2015; 72:227-229.
27. Miller GE, Yu T, Chen E and Brody GH. Self-control forecasts better psychosocial outcomes but faster epigenetic aging in low-SES youth. Proceedings of the National Academy of Sciences. 2015; 112:10325-10330.
28. Costello S, Cockburn M, Bronstein J, Zhang X and Ritz B. Parkinson's Disease and Residential Exposure to Maneb and Paraquat From Agricultural Applications in the Central Valley of California. American Journal of Epidemiology. 2009; 169:919-926.
29. Ritz B, Lee PC, Lassen CF and Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology. 2014; 83:1396-1402.
30. Wang A, Cockburn M, Ly TT, Bronstein JM and Ritz B. The association between ambient exposure to organophosphates and Parkinson's disease risk. Occup Environ Med. 2014; 71:275-281.
31. Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G, Franceschi C, Passeri M and Sansoni P. Expansion of cytotoxic CD8+ CD28-T cells in healthy ageing people, including centenarians. Immunology. 1996; 88:501-507.
32. Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lavagetto G, Casti A, Franceschi C, Passeri M and Sansoni P. Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging. Blood. 2000; 95:2860-2868.
33. Gruver AL, Hudson LL and Sempowski GD. Immunosenescence of ageing. The Journal of Pathology. 2007; 211:144-156.
34. Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S and Buendia E. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol. 2001; 113:146-152.
35. Calopa M, Bas J, Callen A and Mestre M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis. 2010; 38:1-7.
36. Niwa F, Kuriyama N, Nakagawa M and Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int. 2012; 12:102-107.
37. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2012; 7:927-938.
38. Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, Ward C and Halliday GM. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol. 2012; 252:95-99.
39. Akil E, Bulut A, Kaplan I, Ozdemir HH, Arslan D and Aluclu MU. The increase of carcinoembryonic antigen (CEA), highsensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. Neurol Sci. 2015; 36:423-428.
40. Ji KA, Eu MY, Kang SH, Gwag BJ, Jou I and Joe EH. Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia. 2008; 56:1039-1047.
41. Jowaed A, Schmitt I, Kaut O and Wüllner U. Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains. The Journal of Neuroscience. 2010; 30:6355-6359.
42. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S and Iwata A. CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease. PLoS ONE. 2010; 5:e15522.
43. Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, Adame A, Rockenstein E and Masliah E. a-Synuclein Sequesters Dnmt1 from the Nucleus. Journal of Biological Chemistry. 2011; 286:9031-9037.
44. Klemera P and Doubal S. A new approach to the concept and computation of biological age. Mech Ageing Dev. 2006; 127:240-248.
45. Houseman E, Accomando W, Koestler D, Christensen B, Marsit C, Nelson H, Wiencke J and Kelsey K. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012; 13:86.